Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Review Article

Recent Advances in siRNA Delivery Systems for Prostate Cancer Therapy

Author(s): Shahin Aghamiri*, Pourya Raee, Shiva Shahmohamadnejad, Sasan Shabani, Jaber Ghorbani, Marzieh Sameni and Mohammad Taha Ebrahimi

Volume 23, Issue 4, 2022

Published on: 15 June, 2021

Page: [579 - 593] Pages: 15

DOI: 10.2174/1389201022666210615123211

Price: $65

Abstract

Abstract: The critical problems of conventional prostate cancer therapeutic strategies like nonspecific toxicity and multi-drug resistance prompted the development and application of countless nanoparticle- based siRNA therapeutics. Unfortunately, siRNA-based therapeutics suffer from the lack of safe and effective delivery systems, immune system stimulation, poor knowledge of nano-bio interactions, and limitations concerning designing, manufacturing, clinical translation, and commercialization. In this review, we provide cutting-edge advances in nanoparticle-mediated siRNA delivery carriers like polymeric systems, lipid systems, specific systems, and rigid nanoparticles for the treatment of prostate cancer. Moreover, co-delivery of conventional chemotherapy drugs with siRNA as a revolutionary robust strategy for prostate cancer combinational therapy is completely covered.

Keywords: Prostate cancer, nanoparticles, siRNA, drug delivery systems, multidrug resistance, combination therapy.

Graphical Abstract


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy